Shares of BioNTech BNTX rose 5.6% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 767.86% year over year to $1.87, which beat the estimate of ($0.18).
Revenue of $411,870,000 rose by 1225.19% year over year, which beat the estimate of $224,870,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Mar 30, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/j78pn8zg
Technicals
Company's 52-week high was at $131.00
52-week low: $37.00
Price action over last quarter: down 7.46%
Company Overview
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.